7 Result(s)
within
WeiZhou Zhang
Science, Humanities and Social Sciences, multidisciplinary
English
-
Article
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling
In a mouse model of ErbB-driven mammary tumours, Tan et al. find a role for RANKL (receptor activator of nuclear factor-κB ligand) in the formation of lung metastases. RANKL is produced by regulatory T cells infi...
-
Article
Open AccessPTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype
PTEN is a tumour suppressor frequently mutated in many types of cancers. Here we show that targeted disruption of PTEN leads to neoplastic transformation of human neural stem cells (NSCs), but not mesenchymal ...
-
Article
Open AccessObesity-associated NLRC4 inflammasome activation drives breast cancer progression
Obesity is associated with an increased risk of develo** breast cancer and is also associated with worse clinical prognosis. The mechanistic link between obesity and breast cancer progression remains unclear...
-
Article
Open AccessProteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
Regulatory T cells (Tregs) play an important role in maintaining immune homeostasis and, within tumors, their upregulation is common and promotes an immunosuppressive microenvironment. Therapeutic strategies t...
-
Article
Open AccessCD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells
Regulatory T (Treg) cells are one of the major immunosuppressive cell types in cancer and a potential target for immunotherapy, but targeting tumor-infiltrating (TI) Treg cells has been challenging. Here, usin...
-
Article
Open AccessThe GPR171 pathway suppresses T cell activation and limits antitumor immunity
The recently identified G-protein-coupled receptor GPR171 and its ligand BigLEN are thought to regulate food uptake and anxiety. Though GPR171 is commonly used as a T cell signature gene in transcriptomic stud...
-
Article
Open AccessDevelopment of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug development platform. However, most PROTACs have been generated empirically because many determinants of PROTAC specificity and activ...
